Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Telomir Pharmaceuticals, Inc. (TELO) had Consolidated Net Income/Loss of $-1.10M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-1.10M |
|
-- |
|
-- |
|
$1.15M |
|
$-1.15M |
|
$0.04M |
|
$-1.10M |
|
$-1.10M |
|
$-1.10M |
|
$-1.10M |
|
|
Consolidated Net Income/Loss |
$-1.10M |
$-1.10M |
|
$-1.15M |
|
$-1.15M |
|
32.40M |
|
32.40M |
|
$-0.03 |
|
$-0.03 |
|
| Balance Sheet Financials | |
$7.40M |
|
-- |
|
-- |
|
$7.40M |
|
$0.42M |
|
-- |
|
-- |
|
$0.42M |
|
$6.98M |
|
$6.98M |
|
$6.98M |
|
33.83M |
|
| Cash Flow Statement Financials | |
$-2.49M |
|
-- |
|
$8.55M |
|
$1.27M |
|
$7.33M |
|
$6.06M |
|
$5.30M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
17.51 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-2.49M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-15.79% |
|
-15.79% |
|
-14.89% |
|
-15.79% |
|
$0.21 |
|
$-0.08 |
|
$-0.08 |
|